An evaluation of toxicity and outcomes in West of Scotland patients receiving second line treatment of non-small cell lung cancer

被引：0
|
作者：
Laskey, J. [1 ]
MacLean, F. [1 ]
机构：
[1] NHS Greater Glasgow & Clyde, Glasgow, Lanark, Scotland
来源：
LUNG CANCER | 2014年 / 83卷
关键词：
D O I：
10.1016/S0169-5002(14)70015-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
14
引用
收藏
页码：S5 / S6
页数：2
相关论文
共 50 条
  • [31] Efficacy and Toxicity of Pemetrexed as a Third-line Treatment for Non-small Cell Lung Cancer
    Sun, Jong-Mu
    Lee, Keun-Wook
    Kim, Jee Hyun
    Kim, Yu Jung
    Yoon, Ho Il
    Lee, Jae-Ho
    Lee, Choon-Taek
    Lee, Jong Seok
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (01) : 27 - 32
  • [32] Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first second, and third-line
    Al-Farsi, Abdulaziz
    Ellis, Peter Michael
    [J]. FRONTIERS IN ONCOLOGY, 2014, 4
  • [33] Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer
    Feliu, J.
    Martin, G.
    Castro, J.
    Sundlov, A.
    Rodriguez-Jaraiz, A.
    Casado, E.
    Lomas, M.
    Madronal, C.
    Galan, A.
    Belda, C.
    Gonzalez-Baron, M.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (04) : 527 - 531
  • [34] Second-line treatment for advanced non-small cell lung cancer:: A systematic review
    Barlési, F
    Jacot, W
    Astoul, P
    Pujol, JL
    [J]. LUNG CANCER, 2006, 51 (02) : 159 - 172
  • [35] Switch Maintenance versus Second-Line Treatment in Non-small Cell Lung Cancer
    Rossi, Antonio
    Torri, Valter
    Gridelli, Cesare
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (07) : 1298 - 1298
  • [36] Advanced non-small cell lung cancer. Maintenance and second-line treatment
    Schuette, W.
    Nagel, S.
    Haak, G.
    Steinert, M.
    [J]. PNEUMOLOGE, 2012, 9 (01): : 43 - 48
  • [37] Expert recommendation 2006 for rational second line treatment in non-small cell lung cancer
    Hilbe, Wolfgang
    Aigner, Kurt
    Dittrich, Christian
    Eckmayr, Josef
    Fiegl, Michael
    Flicker, Martin
    Forstner, Bernhard
    Greil, Richard
    Jamnig, Herbert
    Krajnik, Gerhard
    Lang, Alois
    Mohn-Staudner, Andrea
    Schinko, Herwig
    Studnicka, Michael
    Pirker, Robert
    Ploner, Ferdinand
    Rothmund, Johannes
    Schiller, Lothar
    August, Zabernigg
    Zochbauer-Muller, Sabine
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2007, 119 (7-8) : 259 - 266
  • [38] Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer
    J. Feliu
    G. Martín
    J. Castro
    A. Sundlov
    A. Rodriguez-Jaráiz
    E. Casado
    M. Lomas
    C. Madroñal
    A. Galán
    C. Belda
    M. Gonzalez-Barón
    [J]. Cancer Chemotherapy and Pharmacology, 2006, 58 : 527 - 531
  • [39] Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)
    Ardizzoni, A
    Tiseo, M
    [J]. JOURNAL OF CHEMOTHERAPY, 2004, 16 : 104 - 107
  • [40] Cisplatin combination regimen in the second-line treatment of non-small cell lung cancer
    Altundag, O.
    Mertsoylu, H.
    Akcall, Z.
    Sakalli, H.
    Ozyilkan, O.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345